Abstract
Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin ......
小提示:本篇文献需要登录阅读全文,点击跳转登录